Skip to main content
NCBI home page
Journal of Cancer Research and Clinical Oncology logoLink to Journal of Cancer Research and Clinical Oncology
editorial
. 1992 Feb;119(2):76–86. doi: 10.1007/BF01209660

Drug resistance in oncology: from concepts to applications

Jean-Louis Cazin 1,✉, Patricia Gosselin 1, Paul Cappelaere 2, Jacques Robert 3, Alain Demaille 2
PMCID: PMC12201294  PMID: 1429830

Abstract

The complex problem of drug resistance is discussed with respect to host toxicity, to tumor characteristics (kinetic resistance, heterogeneity of cell subpopulations, hypoxia, mutation and gene amplification), and to the medication itself (pharmacokinetic and pharmacodynamic resistance: cell membrane, intracellular metabolism, intracellular target). After detailing each type of resistance, the possibilities of fighting against drug resistance are explored (dealing with host toxicity, tumor characteristics and drugs — intensifying therapy, multiple drug therapy, biochemical modulation, particular modalities of drug administration). Finally, perspectives of research and development of new drugs are summarized.

Key words: Oncopharmacology, Resistance to chemotherapy, PgP, GST, Topoisomerases

Footnotes

The “Journal of Cancer Research and Clinical Oncology” publishes in loose succession “Editorials” and “Guest editorials” on current and/or controversial problems in experimental and clinical oncology. These contributions represent exclusively the personal opinion of the author

References

  1. Albrecht AM, Biedler JL (1984) Acquired resistance of tumor cells to folate antagonists. In: Sirotnak FM, Burchall JJ, Ensminger WB, Montgomery JA (eds) Folate antagonists as therapeutic agents. Academic Press, Orlando, pp 317–347 [Google Scholar]
  2. Alt FW, Kellems RE, Bertino JR, Schimke RT (1978) Selective multiplications of dihydrofolate reductase genes in methotrexate resistant variants of cultured murine cells. J Biol Chem 253:1351–1370 [PubMed] [Google Scholar]
  3. Armand JP, Cano JP, Fabre G, Gouyette A, Rahmani R, Riva C, Robert J (1986) Chimiothérapie. In: Tubiana M (ed) Thérapeutique des cancers. Flammarion Médicine Sciences, Paris, pp 193–287 [Google Scholar]
  4. Baguley BC, Holdaway KM, Fray LM (1990) Design of DNA intercalators to overcome topoisomerase II-mediated multidrug resistance. JNCI 82:398–402 [DOI] [PubMed] [Google Scholar]
  5. Bech-Hansen NT, Till JE, Ling V (1976) Pleiotropic phenotype of colchicine-resistant CHO cells: cross resistance and collateral sensitivity. J Cell Physiol 88:23–31 [DOI] [PubMed] [Google Scholar]
  6. Beck WT (1990) Strategies to circumvent multidrug resistance tue to P-glycoprotein or to altered DNA topoisomerase II. Bull Cancer 77:1131–1141 [PubMed] [Google Scholar]
  7. Beck WT, Cirtain MC, Danks MK, Felsted RL, Safaa R, Wolverton JS, Suttle DP, Trent JM (1987) Pharmacological, molecular and cytogenetic analysis of, “atypical” multidrug-resistant human leukemic cells. Cancer Res 47:5455–5460 [PubMed] [Google Scholar]
  8. Benet JZ, Mitchell JR, Sheiner LB (1990) Pharmacokinetics: the dynamics of drug absorption, distribution and elimination. In: Gilman Gooman A, Rallt W, Nies AS, Taylor P(eds) The pharmacological basis of therapeutics. Pergamon, New York, pp 3–32 [Google Scholar]
  9. Biedler JL, Riehm H (1970) Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross resistance, radioautographic and cytogenetic studies. Cancer Res 30:1174–1184 [PubMed] [Google Scholar]
  10. Biedler JL Spengler B (1971) Metaphase chromosome anomaly association with drug resistance and cell-specific products. Science 191:185–187 [DOI] [PubMed] [Google Scholar]
  11. Brown JM (1979) Evidence for acutely hypoxic cells in mouse tumours and a possible mechanism of reoxygenation. Br J Radiol 52:650–656 [DOI] [PubMed] [Google Scholar]
  12. Brown JM (1990) Tumor hypoxia, drug resistance and metastases. JNCI 82:338–339 [DOI] [PubMed] [Google Scholar]
  13. Bungo M, Fujiwara Y, Kasahara K, Nakawa K, Ohe Y, Sasaki Y, Irino S, Saijo N (1990) Decreased accumulation as a mechanism of resistance tocis-diamminedichloroplatinum (II) in human non-small cell lung cancer cell lines: relation to DNA damage and repair. Cancer Res 50:2549–2553 [PubMed] [Google Scholar]
  14. Cabral F, Sobel ME, Gottesman MM (1980) CHO mutants resistant to colchicine, colcemid or griseofulvin have an altered β-tubulin. Cell 20:29 [DOI] [PubMed] [Google Scholar]
  15. Calvert AH (1989) Introduction: a history of the progress of anticancer chemotherapy. Cancer Surv 8:493–510 [PubMed] [Google Scholar]
  16. Calvo F, Bertin L, De Cremoux P, Lagier G, Marty M (1989) Les marqueurs de la chimiorésistance. In: Bolla M, Martin P (eds) Les marqueurs tumoraux plasmatiques, tissulaires, génomiques. Masson, Paris, pp 211–218 [Google Scholar]
  17. Cazin JL, Gosselin P, Touitou Y (1991) Chronobiologie: le temps est venu: II. De la pathologie à la thérapeutique. J Pharm Clin 10:45–53 [Google Scholar]
  18. Cenciarelli C, Currier SJ, Willingham MC, Thiebaut F, Germann UA, Rutherford AV, Gottesman MM, Barca S, Tombesi M, Morrone S, Santoni A, Mariani M, Ramoni C, Dupuis ML, Cianfriglia M (1991) Characterization by somatic cell genetics of a monoclonal antibody to the mdrl gene product (P-glycoprotein): determination of P-glycoprotein expression in multidrug resistant K.B. and cell variants. Int J Cancer 47:533–543 [DOI] [PubMed] [Google Scholar]
  19. Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, Roninson TB (1986) Internal duplication and homology with bacterial transport protein in mdr-1 (P-glycoprotein) gene from multidrug resistant human cells. Cell 47:381–389 [DOI] [PubMed] [Google Scholar]
  20. Coleman CN (1989) Chemical modification of radiation and chemotherapy. In: De Vita VT, Hellman S, Rosenberg SA (eds) Cancer; principles and practice of oncology. Lippincott, Philadelphia, pp 2436–2449 [Google Scholar]
  21. Connors TA (1989) Has chemotherapy any where to go? Cancer Surv 8:693–705 [PubMed] [Google Scholar]
  22. Curt GA, Carney DN, Cowan KH (1983) Unstable methotrexate resistance in human small cell carcinoma associated with double minute chromosomes. N Engl J Med 308:199–202 [DOI] [PubMed] [Google Scholar]
  23. Deisseroth AB (1989) Molecular and genetic approaches to cancer diagnosis and treatment. In: De Vita VT, Hellman S, Rosenberg SA (eds) Cancer; principles and practice of oncology. Lippincott, Philadelphia, pp 2413–2426 [Google Scholar]
  24. De Vita VT (1990) The problem of resistance keynote adress. In: Mihich E (ed) Drug resistance: mechanisms and reversal. John Libbey CIC, Roma, pp 7–27 [Google Scholar]
  25. De Vita VT (1991) The influence of information on drug resistance on protocol design. Ann Oncol 2:93–106 [DOI] [PubMed] [Google Scholar]
  26. Dhir R, Buschman E, Gros P (1990) Structural and functional characterization of the mouse multidrug resistance gene family. Bull Cancer 77:1125–1129 [PubMed] [Google Scholar]
  27. D'incalci M, Citti L, Taverna P, Catapano CV (1988) Importance of DNA repair enzyme 06 alkyl transferase (AT) in cancer chemotherapy. Cancer Treat Rev 15:279–282 [DOI] [PubMed] [Google Scholar]
  28. Endressen L, Schjerven L, Rugstad HE (1984) Tumours from a cell strain with a high content of metallothionein show enhanced resistant againstcis-dichlorodiammine platinum. Acta Pharmacol Toxicol 55:183–187 [DOI] [PubMed] [Google Scholar]
  29. Epstein RJ (1990) Drug-induced DNA damage and tumor chemosensitivity. J Clin Oncol 8:2062–2084 [DOI] [PubMed] [Google Scholar]
  30. Erlichmann C, Fine S, Wong A, Elhakim T (1988) A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 6:469–475 [DOI] [PubMed] [Google Scholar]
  31. Fabre I, Fabre G, Goldman ID (1984) Polyglutamylation, an, important element in methotrexate cytotoxicity and selectivity in tumor versus cells in vitro. Cancer Res 44:3190–3195 [PubMed] [Google Scholar]
  32. Fine RL, Jett M, Patel J, Carmichaels J, Ahn CH (1989) Phosphoprotein, protein kinase C and second messenger system changes in human multidrug-resistant cancer cells. In: Ozols RF (ed) Drug resistance in cancer therapy. Kluwer, Boston, pp 107–123 [DOI] [PubMed] [Google Scholar]
  33. Fitzgerald DJ, Willingham MC, Cardarelli CO (1987) A monoclonal antibody-Pseudomonas toxin congugate that specificelly kills multidrug-resistant cells. Proc Natl Acad Sci USA 84:4288–4292 [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Foote SJ, Kyle DE, Martin RK, Oduola AMJ, Forsyth K, Cowman AF (1990) Several alleles of the multidrug resistance gene are closely linked to chloroquine resistance inPlasmodium falciparum. Nature 345:255–258 [DOI] [PubMed] [Google Scholar]
  35. Ford JM, Hait WN (1990) Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42:155–199 [PubMed] [Google Scholar]
  36. Fuqua SAW, Merker DE, McGuire WL (1988) Laboratory aspects of multidrug resistance. In: Muggia FM (ed) Cancer chemotherapy; concepts, clinical investigations and therapeutic advances. Kluwer, Boston, pp 45–49 [Google Scholar]
  37. Gennis RB (1989) Biomembranes. Molecular structure and function. Springer. New York Berlin Heidelberg [Google Scholar]
  38. Gerlach JH, Endicot JA, Juranka PF, Henderson G, Sarangi F, Deuchars KL, Ling V (1986) Homology between P-glycoprotein and a bacterial haemolysin transport protein suggest a model for multidrug resistance. Nature 324:485–489 [DOI] [PubMed] [Google Scholar]
  39. Goldie JH, Coldman AJ (1979) The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res 44:3643–3653 [PubMed] [Google Scholar]
  40. Goldie J, Coldman A, Gudausmas G (1982) Rationale for the use of alternating non-cross resistance chemotherapy. Cancer Treat Rep 66:439–445 [PubMed] [Google Scholar]
  41. Goldin A (1989) Historical aspects pertaining to the problem of tumor resistance to chemotherapy. In: Kessel D (ed) Resistance to antineoplastic drugs. CRC, Boca Raton, pp 1–13 [Google Scholar]
  42. Goldstein LJ, Gottesman MM, Pastan I (1991) Expression of the mdr1 gene in human cancers. In: Ozols RF (ed) Molecular and clinical advances in anticancer drug resistance. Kluwer, Boston, pp 101–119 [DOI] [PubMed] [Google Scholar]
  43. Gottesman MM, Pastan I (1988) Resistance to multiple chemotherapeutic agents in human cancer cells. Trends Pharmacol Sci 9:54–58 [DOI] [PubMed] [Google Scholar]
  44. Gottesman MM, Pastan I (1989) Clinical trials of agents that reverse multi-drug resistance. J Clin Oncol 7:409–411 [DOI] [PubMed] [Google Scholar]
  45. Gros P, Croop J, Housman D (1986a) Mammalian multidrug resistance gene complete cDNA sequence indicates strong homology to bacterial transport protein. Cell 47:371–380 [DOI] [PubMed] [Google Scholar]
  46. Gros P, Ben Neriah Y, Croop JM, Housman DE (1986b) Isolation and expression of a cDNA (mdr) that confers multidrug resistance. Nature 323:728–731 [DOI] [PubMed] [Google Scholar]
  47. Grunberg SM (1990) Making chemotherapy easier. N Engl J Med 322:846–848 [DOI] [PubMed] [Google Scholar]
  48. Hamada H, tsuruo T (1986) Functional role of the 170 to 180 KDa glycoprotein specific to drug-resistant tumour cells as revealed by monoclonal antibodies. Proc Natl Acad Sci USA 83:7785–7789 [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Hamada H, Miura K, Ariyoshi K, Heike Y, Sato S, Kameyama K, Kurosawa Y, Tsuruo T (1989) Mouse-human chimeric antibody against the multidrug transporter P-glycoprotein. Cancer Res 50:3167–3171 [PubMed] [Google Scholar]
  50. Heppner GH (1984) Tumor heterogeneity. Cancer Res 44:2259–2265 [PubMed] [Google Scholar]
  51. Herweijer H, Sonneveld P, Baas F, Nooter K (1990) Expression of mdr1 and mdr3 multidrugresistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporin. JNCI 82:1133–1140 [DOI] [PubMed] [Google Scholar]
  52. Hrushesky W (1985) Circadian timing of cancer chemotherapy. Science 228:73–75 [DOI] [PubMed] [Google Scholar]
  53. Hryniuk WM (1987) Average relative dose intensity and the impact on design of clinical trials. Seminin Oncol 14:65–74 [PubMed] [Google Scholar]
  54. Hryniuk WM (1989) The importance of dose intensity in the outcome of chemotherapy. In: De Vita VT, Hellman S, Rosenberg SA (eds) Cancer; principles and practice of oncology. Lippincott, Philadelphia, pp 121–142 [Google Scholar]
  55. Hu XF, Martin TJ, Bell DR, Deluise M, Zalcberg JR (1990) Combined use of cyclosporin A and verapamil in modulating multidrug resistance in human leukemia cell lines. Cancer Res 50:2953–2957 [PubMed] [Google Scholar]
  56. Juliano RL, Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152–162 [DOI] [PubMed] [Google Scholar]
  57. Kartner N, Riordan JR, Ling V (1983) Cell surface P-glycoprotein as associated with multidrug resistance in mammalian cell lines. Science 221:1285–1288 [DOI] [PubMed] [Google Scholar]
  58. Kartner N, Evenden-Porelle D, Bradley G, Ling V (1985) Detection of P-glycoprotein in multidrug resistant cell lines by monoclonal antibodies. Nature 316:820–823 [DOI] [PubMed] [Google Scholar]
  59. Kaufman RJ, Brown PC, Schimke RT (1979) Amplified dihydrofolate reductase genes in unstably methotrexate-resistant tumor cells is associated with double minutes chromosomes. Proc Natl Sci USA 76:5669 [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Kellen JA (1991) Drug resistance, the last frontier. Anticancer Res 11:917–920 [PubMed] [Google Scholar]
  61. Kelley SL, Basu A, Teicher BA, Hacker MP, Hamer DH, Lazo JS (1988) Overexpression of metallothionein confers resistance to anticancer drugs. Science 241:1813–1815 [DOI] [PubMed] [Google Scholar]
  62. Kuwazuru Y, Hanada S, Furukawa T, Yoshimura A, Sumizawa T, Utsunomiya A, Ishibashi K, Saito T, Uogumi K, Maruyama M, Ishizama M, Arima T, Akiyama S (1990) Expression of P-glycoprotein in adult T-cell leukemia cells. Blood 76:2065–2071 [PubMed] [Google Scholar]
  63. Lai GM, Ozols RF, Young RC, Hamilton TC (1989) Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines. JNCI 81:535–539 [DOI] [PubMed] [Google Scholar]
  64. Law LW (1952) Origin of the resistance of leukemic cells to folic acid antagonists. Nature 169:628–629 [DOI] [PubMed] [Google Scholar]
  65. Ling V, Thompson LH (1973) Reduced permeability in CHO cells as a mechanism of resistance to colchicine. J Cell Physiol 83:103–116 [DOI] [PubMed] [Google Scholar]
  66. Liu LF (1990) Topoisomerase poisons in cell killing and drug resistance. In: Mihich E (ed) Drug resistance: mechanisms and reversal. John Libbey, Roma, pp 251–263 [Google Scholar]
  67. Luria SE, Delbrück M (1943) Mutations of bacteria from virus sensitivity to virus resistance. Genetics 28:491–511 [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Ma DDF, Bell DR (1989) Multidrug resistance and P-glycoprotein expression in human cancer. Aust NZ J Med 19:736–743 [DOI] [PubMed] [Google Scholar]
  69. Marty M, Pouillart P, Scholl S, Droz JP, Azab M, Brion M, Pujade-Lauraine E, Paule B, Paes D, Bons J (1990) Comparison of the 5-hydroxy tryptamine 3 (serotonin) antagonist ondansetron (GR 38032 F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 322:816–821 [DOI] [PubMed] [Google Scholar]
  70. Mc Lachlin JR, Eglitis MA, Ueda K, Kantoff PW, Anderson WF, Gottesman MM (1990) Expression of a human complementary DNA for the multidrug resistance gene in murine hematopoietic precursor cells with the use of retroviral gene transfer. JNCI 82:1260–1263 [DOI] [PubMed] [Google Scholar]
  71. Meyers MB, Rittmann-Grauer L, O'brien JP, Safa AR (1989) Characterization of monoclonal antibodies recognizing a Mr 180000 P-glycoprotein: differential expression of the Mr 180000 and Mr 170000 P-glycoprotein in multidrug-resistant human tumor cells. Cancer Res 49:3209–3214 [PubMed] [Google Scholar]
  72. Muggia FM, Norris K (1990) Drug resistance: implication for treatment strategies. Concluding overview. In: Mihich E (ed) Drug resistance: mechanisms and reversal. John Libbey, Roma, pp 331–336 [Google Scholar]
  73. Musto P, Melillo L, Lombardi G, Matera R, Digiorgio G, Carotenuto M (1991) High risk of early resistant relapse for leukaemic patients with presence of multidrug resistance associated P-glycoprotein positive cells in complete remission. Br J Haematol 77:50–53 [DOI] [PubMed] [Google Scholar]
  74. Ohnoshi T, Ohmura T, Takehashi I (1982) Establishement of methotrexate resistant human acute lymphoblastic leukemia cells in culture and effects of folate antagonists. Cancer Res 42:1655–1660 [PubMed] [Google Scholar]
  75. Ozols RF, Lovie KG, Plowman J (1987) Enhanced melphalan toxicity in human ovarian cancer in vitro and in tumor bearing nude mice by buthionine sulfoximine deplation of glutathione. Biochem Pharmacol 36:147–153 [DOI] [PubMed] [Google Scholar]
  76. Pastan I, Gottesman MM (1987) Multiple-drug resistance in human cancer. N Engl J Med 316:1388–1393 [DOI] [PubMed] [Google Scholar]
  77. Pastan I, Gottesman MM (1991) Multidrug resistance. Annu Rev Med 42:277–286 [DOI] [PubMed] [Google Scholar]
  78. Pennock GD, Dalton WS, Roeske WR, Appleton CP, Mosley K, Plezia P, Miller TP, Salmon SE (1991) Systemic toxic effects associated with high-dose verapamil infusion an chemotherapy administration. INCI 83:105–110 [DOI] [PubMed] [Google Scholar]
  79. Phillips RM, Bibby MC, Double JA (1990) A critical appraisal of the predictive value of in vitro chemosensitivity assays. JNCI 82:1457–1468 [DOI] [PubMed] [Google Scholar]
  80. Poupon MF (1989) Acquisition du potentiel métastatique et de la chimiorésistance. Marqueurs connexes de l'évolution des cancers vers la malignité. Pathol Biol 37:1018–1021 [PubMed] [Google Scholar]
  81. Poupon MF, Chevillard S, Roblot-Treupel L, Cuvier C, Millot JM, Bastian G, Couvreur P (1990) Intérêt des nanosphères biodégradables chargées en adriamycine dans le traitement de tumeurs chimiorésistantes. Etude comparative avec la cyclosporine et le vérapamil. Cancer Commun 4:49–50 [Google Scholar]
  82. Powis G, Hickman J, Workman P, Tritton TR, Abita JP, Berdel WE, Gesher A, Moses HL, Nicolson GL (1990) The cell membrane and cell signals as targets in cancer chemotherapy. Cancer Rev 50:2203–2211 [Google Scholar]
  83. Price JE (1990) The biology of metastatic breast cancer. Cancer 66:1313–1320 [DOI] [PubMed] [Google Scholar]
  84. Retsky MW, Wardwell RH, Swartzendruber DE, Headley DL (1987) Prospective computerized simulation of breast cancer: a comparison of computer predictions with nine sets of biological data. Cancer Res 47:4982–4987 [PubMed] [Google Scholar]
  85. Riordan JR, Deuchars K, Kartner N, Along N, Trent J, Ling V (1985) Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature 376:817–819 [DOI] [PubMed] [Google Scholar]
  86. Robert J, Poupon MF, Manfait M, Bernard J, Marie JP, Lucas P, Munck JN (1990) Résistance aux médicaments anticancéreux. Bull Cancer 77:1124 [Google Scholar]
  87. Rosen G, Nirenberg A (1986) High-dose methotrexate with calcium leucovorin rescue; a practical guide to its safe and effective use. In: Kimura K (ed) Methotrexate in cancer therapy. Raven New York, pp 103–116 [Google Scholar]
  88. Rothenberg M, Ling V (1989) Multidrug resistance: molecular biology and clinical relevance. JNCI 81:907–910 [DOI] [PubMed] [Google Scholar]
  89. Rowland M, Tozer TN (1989) Clinical pharmacokinetics, Concepts and applications. Lea and Febinger, Philadelphia [Google Scholar]
  90. Rustum YM (1990) Metabolic modulation and resistance to 5 fluorouracil. In: Mihich E (ed) Drug resistance: mechanisms and reversal. John Libbey, Roma, pp 89–100 [Google Scholar]
  91. Sartorelli AC (1988) Therapeutic attack of hypoxic cells of solid tumors: presidential address. Cancer Res 48:775–777 [PubMed] [Google Scholar]
  92. Scanlon KJ, Newman EM, Lu Y, Priest DG (1986) Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 83:8923–8925 [DOI] [PMC free article] [PubMed] [Google Scholar]
  93. Scheper RJ, Bulte JWM, Brakkee JGP (1988) Monoclonal antibody JSB 1 detects a highly conserved epitope on the P-glycoprotein associated with multidrug resistance. Int J Cancer 42:389–394 [DOI] [PubMed] [Google Scholar]
  94. Singer SJ, Nicolson GL (1972) The fluid mosaic model the structure of cell membranes. Science 175:720–731 [DOI] [PubMed] [Google Scholar]
  95. Skipper HE, Schabel FM, Mellet LB (1950) Implications of biochemical cytokinetic, pharmacologic and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother Rep 54:431–450 [PubMed] [Google Scholar]
  96. Skipper HE, Schabel FM, Trader MW, Thomson JR (1961) Experimental evaluation of potential anticancer agents. VI. Anatomical distribution of leukemic cells and failure of therapy. Cancer Res 21:1154 [PubMed] [Google Scholar]
  97. Storb R (1989) Bone marrow transplantation. In: De Vita VT, Hellman S, Rosenberg SA (eds) Cancer; principles and practice of oncology. Lippincott, Philadelphia, pp 2474–2489 [Google Scholar]
  98. Tannock IF (1989) Principles of cell proliferation: cell kinetics. In: De Vita VT, Hellman S, Rosenberg SA (eds) Cancer; principles and practice of oncology. Lippincott, Philadelphia, pp 3–13 [Google Scholar]
  99. Tattersall MNH, Ganeshagura K, Hoffbrand AV (1974) Mechanisms of resistance of human acute leukemia cells to cytosine arabinoside. Br J Haematol 27:39–46 [DOI] [PubMed] [Google Scholar]
  100. Trent JM, Buick RN, Olson S (1984) Cytologic evidence for gene amplification in methotrexate resistant cells obtained from a patient with ovarian adenocarcinoma. J Clin Oncol 2:8–14 [DOI] [PubMed] [Google Scholar]
  101. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1981) Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41:1967–1972 [PubMed] [Google Scholar]
  102. Tubiana M, Malaise EP (1973) Cinétique de prolifération cellulaire des tumeurs et traitements des cancers. Pathol Biol 21:647–664 [PubMed] [Google Scholar]
  103. Ueda K, Cardarelli C, Gottesman MM, Pastan I (1987) Expression of a full-lengh cDNA for the human mdr1 gene confer resistance to colchicine, doxorubicin and vinblastine. Proc Natl Acad Sci USA 84:3004–3008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  104. Vaupel P, Kallinowski F, Okunieff P (1989) Blood flow, oxygen and nutrient supply and metabolic microenvironment of human tumors: a review. Cancer Res 49:6449–6465 [PubMed] [Google Scholar]
  105. Workman P (1990) The cell membrane and cell signal: new targets for novel anticancer drugs. Annals Oncol 1:100–111 [DOI] [PubMed] [Google Scholar]
  106. Young RC (1989) Drug resistance: The clinical problem. In: Ozols RF (ed) Drug resistance in cancer therapy. Kluwer, Boston, pp 1–12 [Google Scholar]

Articles from Journal of Cancer Research and Clinical Oncology are provided here courtesy of Springer

RESOURCES